Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial


如何引用文章

全文:

详细

The article deals with the results of the administration of new cytostatic - eribulin (Halaven). In EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) phase III clinical study, Halaven had been administrated to 6 patients (between 6 and 35 cycles), at that, partial tumor regression was observed in 3 patients and other 3 patients achieved stabilization. Median progression-free survival (PFS) was 15,3 months and median duration of response (DOR) was 13 months in eribulin group, in group of treatment of physician's choice - median PFS was 5,3 and median DOR was 3,3 months. This article demonstrates 3 clinical cases. The authors concluded that eribulin showed high effectiveness and meaningful improvement in overall survival, maintaining the high quality of life.

作者简介

F Ahmetzanov

ГБОУ ВПО Казанский государственный медицинский университет Минздрава России

проф., ректор, зав. каф. онкологии, лучевой диагностики и лучевой терапии

F Ahmetzanova

ГБОУ ВПО Казанский государственный медицинский университет Минздрава России

ассистент каф. онкологии, лучевой диагностики и лучевой терапии

参考

  1. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2009 г. Вестн. Российского онкологического научного центра им. Н.Н.Блохина РАМН. 2011; 22 (3; Прил. 1): 54-92.
  2. Состояние онкологической помощи населению России в 2013 г. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М.: ФГБУ МНИОИ им. П.А.Герцена, 2014.
  3. Morris P.G. Advances in therapy: eribulin improves survival for metastatic breast cancer. Anticancer Drugs 2010; 21 (10): 885-9.
  4. Cardoso F, Harbeck N, Fallowfield L et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow - up. Ann Oncol 2012; 23 (Suppl. 7): 11-9.
  5. NCCN Guidelines Version 3.2014, Invasive Breast Cancer BINV-20. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
  6. Gennari A, Conte P.F, Rosso R et al. Survival of metastatic breast carcinoma patients over a 20-year period. A retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104 (I.8.): 1742-50.
  7. Hirata Y, Uemura D. Halichondrins antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986; 58: 701-10.
  8. Kuznetsov G et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64: 5760-6.
  9. Towle M.J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001; 61: 1013-21.
  10. Jordan M.A et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005; 4: 1086-95.
  11. Okouneva T et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008; 7: 2003-11.
  12. Smith J.A et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010; 49: 1331-7.
  13. Towle M.J et al. Eribulin induces irreversible mitotic blockade: implications of cell - based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 2011; 71: 496-505.
  14. Goel S et al. A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009; 15: 4207-12.
  15. Tan A.R et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 4213-9.
  16. Synold T.W et al. A Phase I pharmacokinetic and target validation study of the novel anti - tubulin agent E7389: A California Cancer Consortium trial. J Clin Oncol 2005; 23 (Suppl. 16): 3036.
  17. Minami H et al. A Phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur J Cancer 2008; 6 (Suppl.): 140 (Abstract 446).
  18. Vahdat L.T et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxanes. J Clin Oncol 2009; 27: 2954-61.
  19. Cortes J et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010; 28: 3922-8.
  20. Twelves C, Loesch D et al. Updated survival analysis of a Phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in subjects with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2010; San Antonio, TX, USA; p. 6-14-8.

版权所有 © Consilium Medicum, 2014

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##